Drug intelligence / Profile preview

FX007

Development stage: Discontinued
Lead developer: Pacira BioSciences
Modality: Small Molecules
Administration: Intraarticular, Local Injection

Overview

FX007 is an investigational, locally administered small‑molecule nerve growth factor receptor (TrkA) antagonist formulated in a biodegradable PLGA microsphere system for sustained intra-articular delivery to treat pain. Developed originally by AstraZeneca and subsequently by Flexion Therapeutics, the drug was evaluated for post‑operative and osteoarthritis-related pain, aiming to provide prolonged local analgesia by inhibiting TrkA-mediated nociceptive signaling while minimizing systemic exposure. Development has been discontinued after early- to mid‑stage clinical studies.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on FX007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FX007.

Explore the full profile